Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MiNK Therapeutics, Inc. (INKT : NSDQ)

• Company Description    MiNK Therapeutics Inc. is a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases. MiNK Therapeutics Inc. is headquartered in New York. Number of Employees: 33

• Price / Volume Information    Yesterday's Closing Price: $1.31 Daily Weekly Monthly 20 Day Moving Average: 45,402 shares Shares Outstanding: 33.56 (millions) Market Capitalization: $43.96 (millions) Beta: 52 Week High: $22.16 52 Week Low: $1.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -43.04% -35.86% 12 Week -54.36% -49.82% Year To Date -70.63% -64.39%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 149 Fifth Avenue Suite 500 - New York,NY 10010 USA ph: 212-994-8250 fax: - investor@minktherapeutics.com http://www.minktherapeutics.com

• General Corporate Information    Officers Jennifer S. Buell - President and Chief Executive Officer Garo H. Armen - Chairman Christine M. Klaskin - Treasurer Peter Behner - Director Brian Corvese - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 603693102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/09/22 Share - Related Items Shares Outstanding: 33.56 Most Recent Split Date: (:1) Beta: Market Capitalization: $43.96 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.24 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.96 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.54 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -27.78% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - - 12/31/21 - - 09/30/21 - - Current Ratio 03/31/22 - 1.88 12/31/21 - 2.41 09/30/21 - 0.04 Quick Ratio 03/31/22 - - 12/31/21 - 2.41 09/30/21 - 0.04 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 0.52 12/31/21 - 0.71 09/30/21 - -2.35 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - - Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - -

Powered by Zacks Investment Research ©